Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S P Dix

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Current Clinical Topics in Infectious Diseases|August 16, 2000
Lipid formulations of amphotericin BS P Dix, V T Andriole
Oncology (Williston Park, N.Y.)|March 29, 2000
High-dose chemotherapy with autologous stem cell rescue in the outpatient settingS P Dix, R B Geller
Pharmacotherapy|July 1, 1996
Cytokine therapy after bone marrow transplantationS P Dix, C E Gilmore
Drugs|March 11, 2000
Oral chemotherapy agents in the treatment of leukaemiaR B Geller, S P Dix
Transplantation|April 27, 1996
Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patientsC L Osowski, S P Dix, L S Lin, et al.
Antimicrobial Agents and Chemotherapy|December 3, 1998
Efficacy of low-dose dopamine in preventing amphotericin B nephrotoxicity in bone marrow transplant patients and leukemia patientsM J Camp, J R Wingard, C E Gilmore, et al.
American Journal of Hematology|November 1, 1995
Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patientsR B Geller, C E Gilmore, S P Dix, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 2, 1998
An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantationC L Osowski, S P Dix, M Lynn, et al.
The Annals of Pharmacotherapy|February 24, 2001
Practice guidelines for lipid-based amphotericin B in stem cell transplant recipientsR E Quilitz, A D Arnold, G R Briones, et al.
Blood|July 13, 2000
A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantationM R Bishop, S R Tarantolo, R B Geller, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Current Clinical Topics in Infectious Diseases|August 16, 2000
Lipid formulations of amphotericin BS P Dix, V T Andriole
Oncology (Williston Park, N.Y.)|March 29, 2000
High-dose chemotherapy with autologous stem cell rescue in the outpatient settingS P Dix, R B Geller
Pharmacotherapy|July 1, 1996
Cytokine therapy after bone marrow transplantationS P Dix, C E Gilmore
Drugs|March 11, 2000
Oral chemotherapy agents in the treatment of leukaemiaR B Geller, S P Dix
Transplantation|April 27, 1996
Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patientsC L Osowski, S P Dix, L S Lin, et al.
Antimicrobial Agents and Chemotherapy|December 3, 1998
Efficacy of low-dose dopamine in preventing amphotericin B nephrotoxicity in bone marrow transplant patients and leukemia patientsM J Camp, J R Wingard, C E Gilmore, et al.
American Journal of Hematology|November 1, 1995
Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patientsR B Geller, C E Gilmore, S P Dix, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 2, 1998
An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantationC L Osowski, S P Dix, M Lynn, et al.
The Annals of Pharmacotherapy|February 24, 2001
Practice guidelines for lipid-based amphotericin B in stem cell transplant recipientsR E Quilitz, A D Arnold, G R Briones, et al.
Blood|July 13, 2000
A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantationM R Bishop, S R Tarantolo, R B Geller, et al.
Pageof 2